PI Industries (PIIND) Q4 25/26 earnings summary

Executive summary

• Navigated a challenging global agrochemical downcycle, with FY26 consolidated revenue at INR 67,137 million, reflecting a 16% year-over-year decline, and maintained resilience through a diversified portfolio and strong customer relationships.

• Pharma business achieved 40% revenue growth, now contributing ~6% of total exports, while the biologicals segment compounded over 20% annually.

• Maintained a strong balance sheet with significant net cash (INR 34,265 million), enabling flexibility for future investments.

• Board approved a final dividend of Rs 10 per share, totaling Rs 15 per share for FY25-26, subject to AGM approval.

• Leadership transition with Joint Managing Director stepping down for health reasons, remaining as non-executive director, and new senior management appointments.

Financial highlights

• Q4 FY26 revenue: INR 15,652 million; full-year FY26 consolidated revenue: INR 67,137 million, with sequential growth in Q4 but a 16% year-over-year decline.

• Gross margin for FY26 at 58%; EBITDA margin at 25% for the full year.

• Net cash position of INR 34,265 million; debt/equity ratio at 0.02; debt-free balance sheet.

• CapEx of INR 11,508 million in FY26, mainly in agrochemicals, pharma, R&D, and electronic chemicals.

• Trade working capital sustained at 139 days of sales, with an increase year-over-year due to inventory build-up.

Outlook and guidance

• Expecting positive revenue growth in FY27, supported by new product launches and scaling of pharma and biologicals.

• Guidance for ETR in FY27 at 23%-24%.

• Growth expected in late single to early double digits, depending on global conditions.

• Continued focus on maintaining gross margins at FY26 levels and heavy investments planned in R&D and market building for FY27.

• Cautious optimism for H2FY27, with climatic uncertainty partially mitigated by higher reservoir levels.